Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01847326 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01847326 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 48 participants.
The verdict
NCT01847326, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin followed by chemoradiation in treating patients with recurrent head and neck cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, fluorouracil, and hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel albumin-stabilized nanoparticle formulation followed by chemoradiation therapy may be an effective treatment for head and neck cancer.
Interventions
- DRUG carboplatin
- PROCEDURE therapeutic conventional surgery
- DRUG fluorouracil
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
- DRUG hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-03-26 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01847326
The ClinicalTrials.gov registry entry for NCT01847326 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT01847326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01847326 about?
NCT01847326 is a clinical study titled "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer". This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin followed by chemoradiation in treating patients with recurrent head and neck cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabili...
What is the current status of trial NCT01847326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-03-26. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT01847326?
The interventions under investigation include: carboplatin (DRUG), therapeutic conventional surgery (PROCEDURE), fluorouracil (DRUG), paclitaxel albumin-stabilized nanoparticle formulation (DRUG), hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT01847326?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.